$113.270
+1.722 (+1.52%)Zum Schluss
INCY-News
INCY-Events
MiniMed Appoints Sheila Denton as General Counsel
MiniMed (MMED) announced that Sheila Denton has been named General Counsel & Corporate Secretary. Denton brings broad-ranging expertise in corporate governance, strategic transactions, intellectual property, and litigation. Most recently, she served as General Counsel, Corporate Secretary, and a member of the Executive Team of Incyte (INCY).
Mirum and Incyte Receive FDA Approval for Atebrioz Drug
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The recommended dose of Atebrioz is 100 mg administered orally, once daily.
Specialised Therapeutics Expands Partnership with Incyte
Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte, to commercialize, distribute, and register ruxolitinib cream in Australia. Under the terms of the expanded agreement, Incyte will remain responsible for the development and manufacturing of ruxolitinib cream, while ST will manage regulatory submissions, medical affairs, marketing, and distribution across Australia.
RBC Capital Expects Incyte to Update KRAS G12D Data
Incyte (INCY) is expected to report updated data for KRAS G12D inhibitor '734, in combination with mFOLFIRINOX and GemNabP, at ESMO in October, with previous data showing "too little" to have drawn any meaningful conclusions, RBC Capital tells investors in a research note. The firm, which has a Sector Perform rating and $109 price target on Incyte shares, believes the update will look "very competitive" and support the ongoing phase III efforts in 1L PDAC and that initial data appears generally comparable to Revolution Medicines' (RVMD) zoldonrasib.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.